First approval

Afamelanotide (Scenesse): the approved drug that treats light by building a tan

Afamelanotide is the first FDA-approved treatment for erythropoietic protoporphyria — a superpotent α-MSH copy that switches on MC1R to build protective pigment independent of sunlight. It's also the regulated medicine the Melanotan lineage actually produced.

By melanocortin.com editorialLast updated 2026

The system spoken back to itself — a sturdier copy of α-MSH offered to people for whom sunlight is not warmth but injury.

Afamelanotide — sold as Scenesse — is the clearest therapeutic use of the melanocortin pigment system: a drug that treats a light-sensitivity disease by building a protective tan on purpose. It is a synthetic, sturdier copy of α-MSH, and it works by doing deliberately what sunlight normally does by accident — switching on MC1R to make dark, shielding pigment.[1]

The disease it treats

Erythropoietic protoporphyria (EPP) is a rare inherited disorder in which a molecule called protoporphyrin IX builds up in the skin. In sunlight that build-up makes the skin burn with intense, disabling pain — so severe that patients often structure their whole lives around avoiding light.[3] Before 2019 there was no approved treatment; the only option was avoidance.

What "sturdier" actually means

Sturdier is not a figure of speech here. It is two amino acids out of thirteen.

α-MSH and afamelanotide are both tridecapeptides — thirteen-residue chains, acetylated at one end and amidated at the other. Read them side by side and they are the same molecule everywhere except positions 4 and 7. Those two changes are the entire difference between a signal the body clears in minutes and a drug that can hold a receptor open for weeks.

Sequence comparison of α-MSH and afamelanotideBoth are thirteen-residue peptides, acetylated at the N-terminus and amidated at the C-terminus. The sequences are identical except at position 4, where methionine becomes norleucine, and position 7, where L-phenylalanine becomes D-phenylalanine.α-MSHafamelanotidethe hormonethe drugAcAcNH₂NH₂1SerSer2TyrTyr3SerSer4MetNle5GluGlu6HisHis7PheD-Phe8ArgArg9TrpTrp10GlyGly11LysLys12ProPro13ValValPosition 4 · methionine → norleucineThe sulfur side-chain is simply gone —a plain hydrocarbon with nothing left to oxidise.Position 7 · L-Phe → D-PheThe mirror image of the residue —a bond human proteases are not shaped to cut.Both termini are blocked too (Ac–, –NH₂): no free ends for the enzymes that trim peptides.
Two of thirteen positions differ. Norleucine at position 4 removes the sulfur that oxidises; D-phenylalanine at position 7 presents a bond human proteases are not shaped to cut.Sequences: FDA label NDA 210797; Hruby et al., PMID 2535874. CAS 75921-69-6.

At position 4, methionine is swapped for norleucine. Methionine carries a sulfur atom in its side chain, and sulfur is the peptide's soft spot — it oxidises readily, and an oxidised α-MSH is a weakened one. Norleucine is the same length and very nearly the same shape, with the sulfur simply gone: a plain hydrocarbon side chain that has nothing left to attack.

At position 7, L-phenylalanine is replaced by its mirror image,D-phenylalanine. Every amino acid in human proteins is the L form, and the enzymes that chew up peptides evolved to fit L-shaped bonds. Flipping one residue leaves the part of the molecule that touches the receptor essentially intact while presenting proteases with a joint they cannot grip. The peptide survives long enough to matter.

Both ends are blocked too — an acetyl group at the front, an amide at the back — so there is no free amine and no free acid for the enzymes that trim peptides from their ends. Taken together, these are not dramatic modifications. They are the minimum required to keep a naturally short-lived signal in circulation, and they produce a molecule far more potent and far longer-lived than the hormone it copies.

That minimalism is easy to miss, and it matters for a reason that has nothing to do with chemistry.

Solid-phase synthesis of afamelanotideOne identical cycle — remove the protecting group, couple the next residue — is repeated thirteen times. The chain is built from the C-terminus, so residue 13 is added first and residue 1 last. The engineered residues enter at cycle 7 (D-phenylalanine) and cycle 10 (norleucine).ONE REPEATING CYCLETHIRTEEN TIMES · BUILT BACKWARDSdeprotectcouple next residuerepeat× 13resin12345678910111213cycle number →cycle 7 — add D-Phea different bottle, same cyclecycle 10 — add Nlea different bottle, same cycleWritten N→C (Ser 1 … Val 13); built the reverse — residue 13 on first, residue 1 last.
The chain is assembled backwards from how it reads, one identical cycle per residue. The two engineered substitutions enter at cycles 10 and 7.Schematic of synthesis structure only — no reagents, conditions or procedure. Sequence per FDA label NDA 210797.

Peptides of this length are built one residue at a time on a solid support, in a repeating cycle that does not change from step to step. The chain grows backwards relative to how the sequence is written, so the residue numbered 13 goes on first and the two substituted positions arrive at cycles 10 and 7. Neither is difficult chemistry. Making a superpotent, protease-resistant α-MSH analogue takes reaching for a different bottle twice in a run of thirteen.

This is worth stating plainly, because it explains the shape of the whole field. What separated afamelanotide from the peptides sold alongside it was never synthesis. It was years of clinical trials, a manufacturing standard, and a regulator willing to look at the results — none of which the grey-market branch of the same lineage ever attempted.

How it works — pigment on demand

Afamelanotide binds predominantly to MC1R and drives eumelanin productionindependently of sunlight.[1] That independence is the whole point. A person with EPP cannot safely build a tan the normal way, because the ultraviolet exposure that would do it is exactly what causes them pain. Afamelanotide supplies the receptor signal directly, so protective pigment accumulates in advance — lengthening the time patients can tolerate light before symptoms start.[1]

The FDA approved it on 8 October 2019 to increase pain-free light exposure in adults with a history of phototoxic reactions from EPP — the first therapy ever cleared for the condition, granted under Priority Review and Orphan Drug designation.[2]

Afamelanotide: protective pigment on demandMC1R is one pigment switch with two possible triggers. Sunlight flips it by accident — but in erythropoietic protoporphyria that same light is the injury. The afamelanotide implant supplies the identical signal deliberately, with no sunlight and ahead of time, so the melanocyte builds protective eumelanin and the shield is already up when light finally arrives.TWO TRIGGERSONE SWITCHSHIELD, ALREADY UP!sunlightnatural α-MSH — but in EPP,the light itself is the injuryafamelanotide implantsame signal, no sun neededsteady release · ~2 monthsMC1Rthe pigment switchmelanocyteprotective pigment — built in advance→ more pain-free time in the lightpheomelanin · fair, unprotectedeumelanin · the protective pigment
One switch, two triggers. Sunlight flips MC1R by accident — but for someone with EPP that light is the injury. The afamelanotide implant supplies the same signal on purpose, with no sun and ahead of time, so protective eumelanin is built in advance and the shield is already up when light finally arrives.

An unusual delivery system

Afamelanotide is as distinctive in form as in mechanism. Rather than a pill or a self-injection, it is a 16 mg controlled-release implant — a bioresorbable rod roughly 1.7 cm long and 1.45 mm across, about the size of a grain of rice — inserted under the skin by a trained clinician about every two months.[1] The peptide is dispersed through a poly(DL-lactide-co-glycolide) matrix that softens as it takes on water, releasing its contents steadily rather than all at once. That design suits a preventive, always-on job: maintaining a baseline of photoprotection rather than reacting dose by dose.

It is worth being precise about what travels where, because the usual mental picture is wrong. The implant sits in the subcutaneous tissue, below both the dermis and the epidermis. The peptide has to migrate upward to reach the melanocytes sitting at the base of the epidermis — and when it arrives, it stops at their surface.

Delivery and fate of the afamelanotide implantThe implant sits in the subcutaneous fat, below the dermis and epidermis. The peptide migrates up to the melanocyte at the base of the epidermis and binds MC1R on its outer surface without entering; cyclic AMP carries the signal inside. The polymer matrix is hydrolysed to lactate and glycolate, and the peptide is broken down separately into amino acids.epidermisdermissubcutis · fatpeptidemigrates upmelanocyte16 mg PLGA implantdetail · the melanocyte surfaceoutside the cellinside the cellcell membraneMC1Rafamelanotidebinds outside —never enterscAMPsecond messengercarries the signal inthe drug gives the instruction; the cell already owns the machineryThen both disappear — by two separate routesthe polymerPLGA + waterlactate + glycolatesmall acids the body already runs on — nothing left behindthe peptidepeptide + proteasesamino acidsreabsorbed; the engineered residues slow this — they don't stop it
The peptide binds MC1R on the outside of the melanocyte and never enters it — what travels inward is a second messenger. Polymer and peptide are then cleared by two separate routes.Implant composition and dimensions: FDA label NDA 210797. Schematic, not to anatomical scale.

MC1R is a G-protein-coupled receptor: seven helices threaded through the cell membrane, with its binding pocket facing outward. Afamelanotide docks into that outward-facing pocket and stays there. Nothing about the drug crosses into the cell. What crosses is a message — cyclic AMP, the cell's own second messenger — and everything downstream of it, the kinases, the transcription factors, the pigment enzymes, is machinery the melanocyte already owns. The drug does not do the work. It gives the instruction.

Two things then disappear, by separate routes. The polymer matrix is not removed; water gradually cleaves it into lactate and glycolate, two small acids the body already runs on, so nothing is left behind to take out. The peptide is broken down independently, cut by proteases into ordinary amino acids and reabsorbed. The engineered residues slow that process considerably. They do not stop it.

Why not just a pill?

The implant is the most-questioned thing about afamelanotide, and the answer is physical rather than commercial. A peptide this size cannot be swallowed to any useful effect. The digestive tract is built to dismantle proteins, and a thirteen-residue chain arriving in the gut is not a drug — it is lunch. Even setting digestion aside, moving from the intestine into the bloodstream means crossing cell membranes, and afamelanotide is poorly equipped for it.

Why afamelanotide is delivered by implant, not by mouthAfamelanotide is about three times the mass of a typical oral drug but only about one and a half times across as an equivalent sphere. The deciding barrier is polarity: of two molecules of identical size, only the polar, charged one is stopped at the membrane. Dersimelagon, a small non-peptidic molecule, crosses and is taken by mouth.the size picture — real, but modesttypical oral drug≤ 500 Daafamelanotide≈ 1647 Dafar heavier — but only ≈ 1.5× across(equivalent sphere estimated from mass)the real decider — polarityoutsideinside+++afamelanotide✕drags awater shellsame size, no charge✓slips acrossidentical size — only the polar one is stoppedTwo molecules, one receptor, two routesafamelanotidea peptide — pays at the border, takes the implantdersimelagona non-peptidic small molecule — taken by mouth
Size is the barrier you can picture. Polarity is the one that actually decides — a molecule of identical size but no charge would cross without trouble.Masses: ChemSpider CAS 75921-69-6; Sato et al., J Med Chem 2024;67:21729. Diameters are equivalent-sphere estimates derived from molar mass, not measurements.

It is tempting to explain this by size alone — a bowling ball will not fit through a keyhole — and size is genuinely part of it. Afamelanotide is roughly two and a half times the mass of a typical oral drug, and stretched into an extended chain it is about as long as a cell membrane is thick. But the size picture is only half right, and the missing half is the more interesting one. A greasy molecule of exactly the same size would slip across without difficulty. What actually stops afamelanotide is polarity: a dozen or so backbone N–H groups and a net positive charge, each of them clinging to water. Dragging that shell of water into the oily interior of a membrane costs far more energy than the crossing is worth, so the molecule stays put.

Which is exactly why dersimelagon exists. It targets the same receptor and drives the same pigment response, but it is not a peptide at all — it is a small, non-peptidic molecule designed from the outset to survive the gut and cross membranes, and it is taken by mouth. The two drugs are a clean illustration of a trade every peptide therapeutic faces: peptides copy the body's own signals with great precision and pay for it at the border, while small molecules cross freely and have to earn their selectivity the hard way.

Afamelanotide got there first, and the implant is the price of arriving as a peptide.

The Melanotan connection

Afamelanotide is also the answer to a common confusion. It began life as"Melanotan-I," one of the α-MSH analogues that came out of early melanocortin research into synthetic tanning agents. Afamelanotide is the branch of that work that was carried all the way through trials to approval — the regulated medicine the lineage produced. The grey-market tanning peptide Melanotan II is the other, unapproved branch. They are relatives, not the same product, and the difference between them is exactly the difference between a tested, approved drug and an unregulated one. See PT-141 vs Melanotan for how tangled this family tree gets.

The honest bottom line

Afamelanotide is a small, elegant proof that the melanocortin pigment switch is genuinely druggable and genuinely useful. It does not cure EPP — it manages it, by turning a cosmetic side effect of melanocortin agonists, skin darkening, into the therapeutic goal. For the receptor it acts on, see MC1R — the pigment switch; for the oral drug chasing the same target, see dersimelagon.

Education, not a protocol

This page explains what afamelanotide is and how it works. It does not provide dosing or usage instructions and is not medical advice. Afamelanotide is a prescription drug for a specific diagnosed condition; treatment decisions belong with a clinician. See the editorial standards.

Common questions

What is afamelanotide (Scenesse)?

Afamelanotide is a synthetic, longer-lasting copy of the natural hormone α-MSH. Sold as Scenesse, it is an FDA-approved drug that activates the MC1R pigment receptor to build up protective skin pigment, used to help people with the rare light-sensitivity disorder erythropoietic protoporphyria (EPP) tolerate more time in the light.

What is afamelanotide approved for?

The FDA approved it on 8 October 2019 — the first treatment ever for EPP — to increase pain-free light exposure in adults with a history of phototoxic reactions from the condition. It is not a cosmetic tanning product; it is an orphan drug for a specific painful disease.

How is afamelanotide given?

Unusually, it is neither a pill nor a self-injection. It is a 16 mg controlled-release implant, about the size of a grain of rice, placed under the skin by a trained clinician roughly every two months. The implant slowly releases the drug, keeping protective pigment topped up.

Is afamelanotide the same as Melanotan?

It shares the same origin. Afamelanotide began as "Melanotan-I," an α-MSH analogue developed from melanocortin research, and it is the regulated, approved medicine that lineage produced. That makes it the legitimate counterpart to Melanotan II — the unapproved grey-market tanning peptide — rather than the same thing sold two ways.

References

  1. 1.US FDA. SCENESSE (afamelanotide) implant, for subcutaneous use — prescribing information. FDA label (NDA 210797) — mechanism, indication, and dosing. 2019. link ↗
  2. 2.Drugs.com. Scenesse (afamelanotide) FDA approval history. Summary of the 8 October 2019 approval for erythropoietic protoporphyria. 2019. link ↗
  3. 3.HCPLive. FDA approves afamelanotide to treat erythropoietic protoporphyria. News coverage of the first FDA-approved EPP therapy. 2019. link ↗